Weight loss drugs like tirzepatide and semaglutide are growing in popularity and offer significant health benefits, but they ...

Gastrointestinal adverse events partially mediated the weight loss effects among patients with obesity who received tirzepatide vs placebo.

Semaglutide and tirzepatide confer greater improvements in life expectancy than naltrexone/bupropion and ...

A real-world study of over 4,000 US patients without type 2 diabetes found that those who persisted with Tirzepatide for at ...

Obesity is a common health problem affecting a considerable (and growing) proportion of adult populations worldwide.1 Although overweight and obesity are usually diagnosed by anthropometry, such as ...

A recent study published in Diabetes Technology & Therapeutics has demonstrated that off-label use of semaglutide and tirzepatide leads to significant reductions in glycated haemoglobin (HbA1c ...

The Outsourcing Facilities Association is appealing a ruling that rejected their request for an injunction against the FDA’s ...

On March 5, 2025, the U.S. District Court for the Northern District of Texas denied the Outsourcing Facilities Association’s motion for a ...

A federal court in Texas has rejected a request by producers of compounded drugs to extend their ability to manufacture ...

This economic evaluation found that although tirzepatide and semaglutide offered substantial long-term health benefits, they were not cost-effective at current net prices. Efforts to reduce the net ...